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1. Introduction 
Iminosugars (also known as polyhydroxylated alkaloids or 
iminocyclitols) are a class of compounds that allow for selective 
inhibition of sugar-processing enzymes. This property offers a 
wide range of therapeutic applications, such as in the fight 
against diabetes, cancer, HIV, obesity, and viral and prion 
infections.1 The malfunctions of one glycosidase enzyme result in 
a relatively rare glycolipid storage disorder, known as Fabry 
disease.2 This is a disorder of glycosphingolipid metabolism 
caused by the deficiency of lysosomal α-galactosidase, which 
results in deposition of excess globotriaosylceramide in blood 
vessels and other organs, with life-threatening consequences. 
Counterintuitively, glycosidase inhibitors could help in treating 
diseases resulting from glucosidase deficiency (from the 
deficiency of these enzymes): at subinhibitory concentrations, 
some iminosugars stabilize the proper folding of the mutated 
enzyme (the active site-specific-chaperone effect), thus allowing 
its transport out of the endoplasmatic reticulum and enhancing its 
glycolytic activity several times.3 1-Deoxy-galactonojirimycin 
(1) was found to be the most active compound for this purpose; 
however, the 1,2-dideoxy-derivative 2, also known as 4-epi-
fagomine, was also found to have considerable α-galactosidase A 
inhibiting activity. In addition, it was found to inhibit non-
lysosomal glucosylceramidase (GAB-2),4 and to suppress the 
level of cytokines, which are associated with inflammation and 
diabetes.5 The corresponding pipecolic acids, such as 3-
hydroxypipecolic acid (3), are constituents of several natural 
products with important biological activity, as well as 
intermediates in the syntheses of biologically active compounds; 
for these reasons, they have attracted considerable attention from 
synthetic chemists.6 Therefore, we set out to develop efficient 
syntheses of these compounds.  
 
Figure 1. 1-deoxygalactonojirimycin (1), 4-epi-fagomine (2) and  (-)-cis-
(2S,3R)-3-hydroxypipecolic acid (3). 
 
Several syntheses of 4-epi-fagomine have been reported, most 
of which use the chiron approach. Chattopadhyay and 
collaborators prepared the compound from D-glucose (14 steps, 
0.3% overall yield); in addition to 4-epi-fagomine, they also 
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The enantioselective synthesis of 4-epi-fagomine was accomplished starting from dioxanone and 
Cbz-protected benyzlamine, in 4 steps, with 18% overall yield. The key feature of this synthetic 
approach is the tactical combination of reactions: organocatalyzed aldolization/reductive 
amination, which allows for a quick formation of heterocyclic rings with defined absolute 
configuration of all stereogenic centers. Two hydroxypipecolic acids and a reduced fagomine 
analogue were also synthesized. 
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prepared the corresponding pipecolic acid.5 Takahata, Kato and 
coworkers synthesized a series of fagomine-type analogues 
(including 4-epi-fagomine), starting from the Garner aldehyde 
(12 steps, 9% yield).7 Aerts, Overkleeft and coworkers prepared a 
series of deoxynojirimycine derivatives, where 4-epi-fagomine 
was obtained from the Garner aldehyde (7 steps, yield not 
indicated).4,8 Fan and coworkers prepared 4-epi-fagomine by the 
isomerisation of fagomine (experimental details not provided).3b 
Vankar and collaborators prepared fagomine analogues of both L- 
and D-series; 4-epi-fagomine was prepared from tri-O-benzyl-
galactal (7 steps, 28% overall yield).9 The most efficient 
synthesis of 4-epi-fagomine, so far, is reported by Timmer, 
Stocker and collaborators: starting from 2-deoxygalactose, the 
target compound was obtained in 6 steps and with 60% overall 
yield.10 
2. Results and discussion 
We designed a catalytic asymmetric synthesis of 4-epi-
fagomine (ent-2), that hinges on a tactical combination of 
reactions: organocatalyzed aldolization/reductive amination, 
which allows for a rapid access to heterocyclic systems with 
defined absolute configuration of all stereogenic centers. The 
synthesis starts from achiral, commercially available small 
molecules, so both enantiomers of the target compound could be 
obtained by a proper choice of a chiral organocatalyst ((R)- or 
(S)-proline). Recently, we have demonstrated the feasibility of 
this approach in total syntheses of natural products (+)-
swainsonine11 and hyacinthacine derivatives.12 Some time ago, 
Joglar, Clapes and coworkers have reported a conceptually 
similar, two-step synthesis of fagomine, starting from 
dihydroxyacetone and a β-aminopropanal derivative.13 In their 
synthesis the aldolization step was catalyzed by D-fructose-6-
phosphate aldolase, and has resulted in syn-stereochemistry of 
the product, characteristic for chemoenzymatic aldolizations. 
Our synthesis commenced with hetero-Michael addition of the 
commercially available carbamate 4 to acrolein (41%; Scheme 
1).14  The resulting adduct 5 was then submitted to the (S)-
proline-organocatalyzed aldol reaction15 with dioxanone (6).16 
The reaction could be performed in either DMF or DMSO, where 
the use of DMF as a solvent gave slightly higher yield (60%). 
However, we prefered the reaction in DMSO, for the reason of 
the superior purity of the product 7 (50-52%), which was 
obtained with complete diastereoselectivity (i.e., exclusively 
anti-isomer). The only side-product of the reaction was the 
product of self-addition of dioxanone, which is easily separable 
by chromatography.  
 
Scheme 1. Synthesis of 4-epi-fagomine ent-2. Reagents and conditions: a) 
acrolein (10 equiv), CSA (20 mol %), CH2Cl2, 0 ° to rt, 3 h, 41%; b)  6 (1.5 
equiv), (S)-Proline (30 mol %), DMF (or DMSO with 5 equiv of  H2O), 4 °C, 
24 h, 60% (52% in DMSO); c) H2, 10% Pd/C, EtOH, 2 h, 78%; d) 3M HCl, 
MeOH, reflux, 4 h, 92%. 
 
Upon exposure of aldol 7 to a hydrogen atmosphere in the 
presence of palladium on charcoal, double deprotection followed 
by the reductive amination afforded piperidine derivative 8 
(78%). Acid-catalyzed deprotection of the dioxane unit then 
completed the shortest synthesis of 4-epi-fagomine (2), so far (4 
steps, 16% overall yield). 
With piperidine derivative 8 in hand, we turned our attention 
towards the synthesis of pipecolic acids (Scheme 2). Protection 
of amine was followed by the acid-catalyzed rearrangement of 
dioxane 9 into thermodynamically more stable dioxolane 10. The 
primary hydroxyl group was sequentially oxidized, first with 
DMP to the aldehyde, and then to the carboxylate 11 by Pinnick-
Lindgren oxidation. Acid-catalyzed removal of the dioxolane in 
11, followed by reductive decarboxybenzylation of 12, gave 
pipecolic acid 13.  
 
 
Scheme 2. Synthesis of pipecolic acid 13. Reagents and conditions: a) 
CbzCl, Et3N, CH2Cl2, 0 °C to rt, 24 h, 86%; b) p-TsOH (0.15 equiv), acetone, 
rt, 24 h, 65%; c) i) DMP (2 equiv), CH2Cl2, 30 min; ii) NaClO2, 
NaH2PO4•H2O, H2O2, CH3CN, 0 ° to rt, 3 h, 77% over two steps; d) 3M HCl, 
MeOH, rt, 2.5 h, 64%; e) H2, Pd/C, EtOH, 1 h, 93%. 
 
Carbamate 9 could also be converted into a more interesting 
synthetic target, namely 3-hydroxypipecolic acid (ent-3; Scheme 
3). To this end, the corresponding xanthate was submitted to 
Barton-McCombie deoxygenation with hypophosphorous acid, as 
a convenient reducing agent. After the acid-catalyzed 
deprotection of dioxane 14, the resulting diol 15 could be 
selectively oxidized to acid 16 by a sequence of reactions 
involving PIDA oxidation followed by the Pinnick-Lindgren 
oxidation. Alternatively, hydrogenolytic deprotection of 
carbamate 15 yielded (-)-4-deoxyfagomine 17. 
 
Scheme 3. Synthesis of pipecolic acid ent-3 and deoxyazasugar 17. 
Reagents and conditions: a) NaH, CS2, THF, MeI, rt, 30 min, 80% ; b) 
H3PO2, Et3N, AIBN (cat.), 1,4-dioxane, reflux, 30 min, 77%; c) 3M HCl, 
MeOH, rt, 1 h, 72%; d) TEMPO (cat.), PIDA, CH2Cl2, rt, 3 h,; e) NaClO2, 
NaH2PO4•H2O, 30% H2O2, -10 °C to rt, 3 h, 45% from 15; f) H2, 10% Pd/C, 
EtOH, 1 h, 90%; g) H2, 10% Pd/C, EtOH, 2 h, 95%. 
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3. Conclusions 
To summarize, enantioselective syntheses of 4-epi-fagomine 
(ent-2), cis-3-hydroxypipecolic acid (13), as well as their two 4-
deoxy analogues (17 and ent-3), are described. These syntheses 
rely on the organocatalyzed aldol addition/reductive amination 
reaction cascade, which allows for the efficient, stereocontrolled 
formation of functionalized nitrogen heterocycles. 
4. Experimental 
 
4.1. General methods 
 
     All chromatographic separations were performed on silica gel, 
10–18 µm, 60 Å (dry-flash), 100–200 µm 60 Å (column 
chromatography), ICN Biomedicals, 60 (0.063-0.200 mm) 
(column chromatography), Merck and ion exchange column 
chromatography (acidic resin DOWEX 50WX8-100). Standard 
techniques were used for the purification of reagents and 
solvents. Petroleum ether (PE) refers to the fraction boiling at 
70–72 °C. NMR spectra were recorded on Bruker Avance III 500 
(1H NMR at 500 MHz, 13C NMR at 126 MHz). Chemical shifts 
are expressed in ppm (δ) using TMS as the internal standard. IR 
spectra were recorded on a Nicolet 6700 FT instrument, and are 
expressed in cm–1. Mass spectra were obtained on Agilent 
technologies 6210 TOF LC/MS instrument (LC: series 1200) and 
LTQ Orbitrap XL hybrid FTMS (Thermo Scientific). Melting 
points were determined on a Electrothermal apparatus and are 
uncorrected. Optical rotations were determined on a Rudolph 
Research Analytical AUTOPOL IV Automatic Polarimeter.  
 
4.2. Benzylbenzyl(3-oxopropyl)carbamate (5)14 
 
     Freshly distilled acrolein (7.0 mL, 104.81 mmol) was added 
with stirring to a cold (0 °C) solution of N-
benzylbenzylcarbamate 4 (2.5 g, 10.36 mmol) and (+)-
camphorsulfonic acid (0.5 g, 2.15 mmol, 20 mol %) in 
dichloromethane (10 mL). After 20 min cooling bath was 
removed and the reaction mixture was stirred for an additional 
3.5 h at room temperature. The reaction mixture was diluted with 
dichloromethane and washed with sat. aq. NaHCO3 (10 mL). The 
organic extract was concentrated in vacuo, diluted with Et2O (20 
mL), washed with water, dried over anh. MgSO4 and 
concentrated. Purification of the residue by dry-flash 
chromatography (SiO2; eluent: petroleum ether/EtOAc = 8/2) 
afforded aldehyde 5 (1.3 g, 41 %) as a colorless liquid. 1H NMR 
(500 MHz, DMSO-d6, 65 ºC): δ 9.64 (t, J=1.7 Hz, 1H), 7.38–7.22 
(m, 10H), 5.15 (s, 2H), 4.50 (s, 2H), 3.55 (t, J=6.8 Hz, 2H), 2.65 
(td, J=6.8, 1.7 Hz, 2H); 13C NMR (126 MHz, DMSO-d6, 65 ºC): 
δ 201.0 (CH), 155.3 (C), 137.7 (C), 136.6 (C), 128.1 (CH), 128.0 
(CH), 127.4 (CH), 127.2 (CH), 127.0 (CH), 126.8 (CH), 66.3 
(CH2), 50.1 (CH2), 42.1 (CH2), 40.6 (CH2);  IR (ATR) v 3063, 
3032, 2950, 1670, 1473, 1422, 1238, 1123, 737, 700 cm-1; 
HRMS (ESI) for C18H20NO3 [M+H]+ calculated: 298.1443; found: 
298.1429. 
 
4.3. Benzylbenzyl((S)-3-((S)-2,2-dimethyl-5-oxo-1,3-dioxan-4-
yl)-3-hydroxypropyl)carbamate (7) 
 
     Method A: A solution of dioxanone 6 (250 mg, 1.92 mmol), 
aldehyde 5 (389 mg, 1.31 mmol) and (S)-proline (48 mg, 0.42 
mmol, 30 mol %) in DMF (3.4 mL) was stirred overnight at 4 ºC. 
The reaction mixture was diluted with water, extracted with 
EtOAc, the combined organic extract was washed with water, 
dried over anh. MgSO4 and concentrated under reduced 
pressure. Purification of the crude product by dry-flash 
chromatography (SiO2; eluent: toluene/EtOAc = 85/15) afforded 
the title aldol 7 (335.8 mg, 60%) as a pale yellow viscous oil. 
     Method B: Dioxanone 6 (390 mg, 3.00 mmol) and water 
(180.0 µL, 10.00 mmol) were added to a cold (0 °C) solution of 
aldehyde 5 (601 mg, 2.02 mmol) and proline (66 mg, 0.57 mmol, 
30 mol %) in DMSO (7.8 mL), and the mixture was vigorously 
stirred for 24 h at 4 ºC. The reaction was quenched by addition of 
brine followed by extraction with EtOAc. The aqueous phase was 
extracted with EtOAc (3 × 15 mL). The combined organic extract 
was dried over anh. MgSO4, filtered and concentrated under 
reduced pressure. Purification of the crude product by dry-flash 
chromatography (SiO2; eluent: toluene/EtOAc = 85/15) afforded 
the title aldol 7 (864.2 mg, 52%) as a pale yellow viscous oil. 
[α]D20 -85.6 (c 1.00, CHCl3); 1H NMR (500 MHz, DMSO-d6, 65 
ºC) δ 7.39–7.19 (m, 10H), 5.13 (s, 2H), 4.68 (bd, J=5.3 Hz, 1H), 
4.47 (s, 2H), 4.23 (d, J=3.8 Hz, 1H), 4.20 (d, J=17.2 Hz, 1H), 
3.95 (d, J=16.8 Hz, 1H), 3.89–3.83 (m, 1H), 3.40–3.24 (m, 2H), 
1.80–1.65 (m, 2H), 1.39 (s, 3H), 1.37 (s, 3H); 13C NMR (126 
MHz, DMSO-d6, 65 ºC) δ 207.6 (C), 155.4 (C), 137.9 (C), 136.7 
(C), 128.1 (CH), 128.0 (CH), 127.4 (CH), 127.1 (CH), 126.9 
(CH), 126.7 (CH), 99.7 (C), 77.8 (CH), 67.0 (CH), 66.4 (CH2), 
66.0 (CH2), 49.7 (CH2), 43.6 (CH2), 30.2 (CH2), 24.3 (CH3), 22.8 
(CH3); IR (ATR) v 3448, 2987, 2939, 1742, 1698, 1423, 1226, 
1088, 736, 700 cm-1; HRMS (ESI) for C24H30NO6 [M+H]+ 
calculated: 428.2068; found: 428.2059. 
 
4.4. (4aS,8S,8aR)-2,2-Dimethylhexahydro-4H-
[1,3]dioxino[5,4-b]pyridin-8-ol (8) 
 
     A mixture of aldol 7 (58.5 mg, 0.14 mmol) and 10% Pd/C 
(30.3 mg, 0.03 mmol) in ethanol (14.0 mL) was stirred for 2 h 
under a hydrogen atmosphere (5 bar). The mixture was filtered 
and concentrated under reduced pressure. Purification of the 
residue by column chromatography (SiO2; eluent: 
dichloromethane/methanol = 1/1) afforded compound 8 (20.0 
mg, 78%) as a white solid. mp 128-130 ºC; [α]D20 -45.3 (c 1.00, 
MeOH); 1H NMR (500 MHz, MeOD) δ 4.17 (dd, J=12.2, 2.3 Hz, 
1H), 4.12–4.11 (m, 1H), 3.66 (dd, J=12.2, 1.6 Hz, 1H), 3.61 
(ddd, J=11.8, 4.8, 3.1 Hz, 1H), 3.11 (ddd, J=13.8, 4.4, 2.1 Hz, 
1H), 2.59 (td, J=13.3, 3.0 Hz, 1H), 2.44–2.41 (m, 1H), 1.76 (ddd, 
J=24.7, 12.6, 4.4 Hz, 1H), 1.63–1.56 (m, 1H), 1.49 (s, 3H), 1.41 
(s, 3H); 13C NMR (126 MHz, MeOD) δ 100.5 (C), 70.7 (CH), 
70.0 (CH), 65.2 (CH2), 52.8 (CH), 44.7 (CH2), 30.0 (CH2), 30.0 
(CH3), 19.0 (CH3); IR (ATR) v 3366, 2991, 2943, 1458, 1381, 
1198, 1057, 971, 837 cm-1; HRMS (ESI) for C9H18NO3 [M+H]+ 
calculated: 188.1281; found: 188.1283. 
 
4.5. (2S,3R,4S)-2-(Hydroxymethyl)piperidine-3,4-diol (ent-4-
epi-fagomine) (ent-2) 
 
A solution of amine 13 (27.7 mg, 0.15 mmol) in solvent mixture 
methanol/3M HCl (5.7 mL, v/v= 2/1) was stirred and heated to 
reflux for 4 h. After the volatiles were removed under reduced 
pressure, the residue was purified by ion exchange column 
chromatography (acidic resin DOWEX 50WX8-100), to give the 
title compound ent-2 (20.1 mg, 92%) as a white solid. mp 219-
221 ºC, [lit.17 mp 220-222 ºC]; [α]D20 -15.5 (c 1.00, H2O), [lit.17 
[α]D20 -10.4 (c 1.02, H2O)]; 1H NMR (500 MHz, D2O) δ 3.93–
3.91 (m, 1H), 3.75 (ddd, J=11.0, 6.1, 2.9 Hz, 1H), 3.65 (ddd, 
J=18.0, 11.5, 6.7 Hz, 2H), 3.13–3.05 (m, 1H), 2.75 (td, J=6.7, 1.5 
Hz, 1H), 2.66–2.58 (m, 1H), 1.75–1.65 (m, 2H); 13C NMR (126 
MHz, D2O) δ 72.5 (CH), 70.3 (CH), 64.3 (CH2), 61.7 (CH), 45.5 
(CH2), 30.0 (CH2); IR (ATR) v 3355, 2938, 1446, 1358, 1057, 
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1025, 805 cm-1; HRMS (ESI) for C6H14NO3 [M+H]+ calculated: 
148.0968; found: 148.0972. 
 
4.6. (4aS,8S,8aR)-Benzyl 8-hydroxy-2,2-dimethyltetrahydro-
4H-[1,3]dioxino[5,4-b]pyridine-5(4aH)-carboxylate (9) 
 
     Benzyl chloroformate (104.7 mg, 0.61 mmol) was added 
dropwise (over a period of 20 min) to a cold (0 °C) solution of 
amine 8 (104.5 mg, 0.56 mmol) and triethyl amine (75.6 mg, 
0.75 mmol) in dichloromethane (0.6 mL). The reaction was 
warmed to room temperature and stirred overnight, then diluted 
with water (10 mL). The mixture was extracted with 
dichloromethane (3 × 20 mL), and the combined organic extract 
was washed with sat. aq. NaHCO3 (2 × 20 mL), brine (20 mL), 
dried over anh. MgSO4, filtered and concentrated under reduced 
pressure. Purification of the residue by column chromatography 
(SiO2; eluent: dichloromethane/methanol = 95/5) afforded the 
title compound 9 (154.3 mg, 86%) as a colorless viscous oil. 
[α]D20 +106.1 (c 1.00, CHCl3); 1H NMR (500 MHz, DMSO-d6, 
65 ºC) δ 7.40–7.29 (m, 5H), 5.08 (dd, J=21.7, 12.6 Hz, 2H), 4.52 
(d, J=5.8 Hz, 1H), 4.18 (dd, J=4.4, 2.3 Hz, 1H), 3.98 (dd, J=12.0, 
4.0 Hz, 1H), 3.87 (ddd, J=13.0, 9.0, 2.0 Hz, 1H), 3.73 (dd, 
J=12.3, 3.4 Hz, 1H), 3.67 (dd, J=8.0, 4.0 Hz, 1H), 3.60 (tdd, 
J=8.5, 5.8, 2.3 Hz, 1H), 3.53 (ddd, J=13.1, 9.8, 7.5 Hz, 1H), 2.02 
(ddd, J=18.3, 12.8, 9.1 Hz, 1H), 1.60–1.50 (m, 1H), 1.40 (s, 3H), 
1.33 (s, 3H); 13C NMR (126 MHz, DMSO-d6, 65 ºC) δ 154.5 (C), 
136.6 (C), 128.0 (CH), 127.4 (CH), 127.2 (CH), 97.8 (C), 67.7 
(CH), 65.9 (CH2), 65.5 (CH), 61.4 (CH2), 48.9 (CH), 38.2 (CH2), 
27.8 (CH3), 27.4 (CH2), 19.7 (CH3); IR (ATR) v 3440, 2988, 
2936, 1695, 1424, 1381, 1262, 1075, 771, 700 cm-1; HRMS (ESI) 
for C17H24NO5 [M+H]+ calculated: 322.1649; found: 322.1647. 
 
4.7. (3aR,4S,7aS)-Benzyl 4-(hydroxymethyl)-2,2-
dimethyltetrahydro-[1,3]dioxolo[4,5-c]pyridine-5(6H)-
carboxylate (10) 
     pTsOH•H2O (14.0 mg, 0.07 mmol) was added to a solution of 
alcohol 9 (153.7 mg, 0.48 mmol) in acetone (6.9 mL), and the 
mixture was stirred at room temperature for 24 h. The reaction 
mixture was treated with triethylamine (14.6 mg, 0.14 mmol) and 
concentrated under reduced pressure. The residue was purified by 
column chromatography (SiO2; eluent: petroleum ether/EtOAc = 
6/4), to afford alcohol 10 (99.9 mg, 65%) as a colorless viscous 
oil. [α]D20 +29.4 (c 1.00, CHCl3); 1H NMR (500 MHz, DMSO-d6, 
65 ºC) δ 7.39–7.28 (m, 5H), 5.09 (s, 2H), 4.42 (dd, J=6.8, 5.8 Hz, 
1H), 4.33–4.28 (m, 2H), 4.07 (dd, J=12.8, 6.8 Hz, 1H), 3.74–3.65 
(m, 2H), 3.53 (ddd, J=13.1, 6.4, 5.0 Hz, 1H), 3.29 (ddd, J=13.2, 
9.2, 4.1 Hz, 1H), 1.88–1.80 (m, 1H), 1.76–1.69 (m, 1H), 1.37 (d, 
J=0.5 Hz, 3H), 1.28 (d, J=0.5 Hz, 3H); 13C NMR (126 MHz, 
DMSO-d6, 65 ºC) δ 155.3 (C), 136.8 (C), 128.0 (CH), 127.3 
(CH), 127.0 (CH), 107.0 (C), 71.4 (CH), 70.3 (CH2), 65.9 (CH2), 
59.6 (CH), 54.2 (CH), 36.9 (CH2), 27.3 (CH2), 26.0 (CH3), 24.3 
(CH3); IR (ATR) v 3462, 2985, 2936, 1697, 1418, 1256, 1212, 
1063, 869, 700 cm-1; HRMS (ESI) for C17H24NO5 [M+H]+ 
calculated: 322.1649; found: 322.1647. 
 
4.8. (3aR,4R,7aS)-5-(Benzyloxycarbonyl)-2,2-
dimethylhexahydro-[1,3]dioxolo[4,5-c]pyridine-4-carboxylic 
acid (11) 
 
     Dess-Martin’s periodinane (268 mg, 0.63 mmol) was added to 
a solution of alcohol 10 (96.7 mg, 0.30 mmol) in 
dichloromethane (3.0 mL) and the reaction mixture was stirred at 
room temperature for 30 min. The reaction mixture was diluted 
with dichloromethane, washed with 5% Na2S2O3 and sat. aq. 
NaHCO3, dried over anh. MgSO4, filtered and concentrated under 
reduced pressure. The residue was further used without 
purification. 
     To a stirred solution of the crude aldehyde (obtained from 10 
(96.7 mg, 0.30 mmol)) in CH3CN (2.1 mL) was added a solution 
of NaH2PO4•H2O (8.2 mg, 0.06 mmol) in H2O (0.4 mL) and 30% 
H2O2 (45.0 µL, 0.57 mmol).5 The mixture was cooled to 0°C, and 
NaClO2 (45.0 mg, 0.50 mmol) in H2O (0.9 mL) was added 
dropwise over a period of 30 minutes. The reaction mixture was 
stirred at 15 °C. After 3 h, the reaction was quenched by the 
addition of a small amount of Na2SO4 (50.0 mg) and extracted 
with EtOAc (3 × 5 mL). Evaporation of the solvent followed by 
column chromatography of the residue (SiO2; eluent: 
dichloromethane/methanol = 95/5) afforded compound 11 (77.7 
mg, 77% over two steps) as a white solid. mp 45-47 °C; [α]D20 
+15.5 (c 1.00, CHCl3); 1H NMR (500 MHz, DMSO-d6, 65 ºC) δ 
7.40–7.26 (m, 5H), 5.12–5.01 (m, 2H), 4.66 (dd, J=6.9, 5.2 Hz, 
1H), 4.42–4.34 (m, 2H), 3.74 (bd, J=12.2 Hz, 1H), 3.25 (bs, 1H), 
1.75–1.64 (m, 2H), 1.38 (s, 3H), 1.27 (s, 3H); 13C NMR (126 
MHz, DMSO-d6, 65 ºC) δ 169.9 (C), 154.9 (C), 136.5 (C), 128.0 
(CH), 127.3 (CH), 127.0 (CH), 106.8 (C), 71.5 (CH), 69.8 (CH), 
66.0 (CH2), 54.6 (CH), 36.1 (CH2), 29.1 (CH2), 26.2 (CH3), 23.9 
(CH3); IR (ATR) v 3741, 2988, 2936, 1702, 1422, 1259, 1214, 
1040, 738 cm-1; HRMS (ESI) for C17H20NO6 [M-H]- calculated: 
334.1296; found: 334.1309. 
 
 
4.9. (2R,3R,4S)-1-(Benzyloxycarbonyl)-3,4-
dihydroxypiperidine-2-carboxylic acid (12) 
 
     A solution of compound 11 (93.5 mg, 0.28 mmol) in solvent 
mixture methanol/3M HCl (12.6 mL, v/v = 2/1) was stirred at 
room temperature for 2 h. After the volatiles were removed under 
reduced pressure, the residue was purified by column 
chromatography (SiO2; eluent: dichloromethane/methanol = 9/1), 
to give the title compound 12 (53.1 mg, 64%) as a colorless, 
viscous oil. [α]D20 +40.8 (c 0.7, MeOH); 1H NMR (500 MHz, 
DMSO-d6, 65 ºC) δ 7.38–7.27 (m, 5H), 5.08 (s, 2H), 4.47 (bs, 
1H), 3.84 (bs, 1H), 3.78–3.62 (m, 2H), 3.30 (bs, 1H), 1.69–1.54 
(m, 2H); 13C NMR (126 MHz, DMSO-d6, 65 ºC) δ 172.6 (C), 
155.1 (C), 136.8 (C), 128.0 (CH), 127.3 (CH), 127.0 (CH), 69.5 
(CH), 66.7 (CH), 65.9 (CH2), 55.1 (CH), 35.0 (CH2), 30.3 (CH2); 
IR (ATR) v 3371, 2951, 1678, 1610, 1413, 1154, 746, 603 cm-1; 
HRMS (ESI) for C14H18NO6 [M+H]+ calculated: 296.1134; found: 
296.1123. 
 
4.10. (2R,3R,4S)-3,4-Dihydroxypiperidine-2-carboxylic acid 
(3,4-Dihydroxypipecolic Acid) (13) 
 
     A suspension of 12 (21.9 mg, 0.07 mmol) and 10% Pd/C (5.3 
mg, 0.005 mmol) in methanol (1.5 mL) was stirred under a 
hydrogen atmosphere (1 bar) for 2 h at room temperature. The 
reaction mixture was filtered through celite, concentrated under 
reduced pressure and purified by column chromatography (SiO2; 
eluent: EtOAc/EtOH/H2O = 4/4/2), to give the title compound 13 
(11.1 mg, 93%) as a white solid. mp 240-242 ºC, [lit.5 for ent-13 
mp 245-247 ºC]; [α]D20 +6.8 (c 0.65, H2O), [lit.5 [α]D25 +7.5 (c 
2.10, H2O)]; 1H NMR (500 MHz, D2O) δ 4.43–4.40 (m, 1H), 
3.97 (ddd, J=11.5, 5.2, 2.8 Hz, 1H), 3.75 (d, J=1.6 Hz, 1H), 3.46 
(ddd, J=13.1, 4.6, 2.3 Hz, 1H), 3.05 (td, J=13.2, 3.8 Hz, 1H), 
2.07–1.90 (m, 2H); 13C NMR (126 MHz, D2O) δ 171.6 (C), 67.8 
(CH), 67.5 (CH), 61.9 (CH), 41.2 (CH2), 23.6 (CH2); IR (ATR) v 
3395, 3313, 3109, 2957, 2926, 2856, 1732, 1458, 1269, 1074 cm-
1; HRMS (ESI) for C6H12NO4 [M+H]+ calculated: 162.0761; 
found: 162.0758. 
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4.11. (4aS,8aS)-Benzyl 2,2-dimethyltetrahydro-4H-
[1,3]dioxino[5,4-b]pyridine-5(4aH)-carboxylate (14) 
 
     To a solution of compound 8 (62.0 mg, 0.19 mmol) in THF 
(0.2 mL) was added sodium hydride (12.0 mg, 0.50 mmol) under 
an argon atmosphere. After stirring for 15 minutes at room 
temperature, carbon disulfide (0.3 mL, 5.10 mmol) was added, 
followed after 0.5 h by iodomethane (65 µL, 1.04 mmol). The 
resulting solution was stirred for 30 minutes and the reaction was 
quenched by addition of water. The mixture was extracted with 
EtOAc, the extract was washed with wather, dried over anh. 
MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by column chromatography (SiO2; eluent: 
petroleum ether/EtOAc = 85/15), to give the xanthate (63.5 mg, 
80%) as a pale yellow viscous oil. [α]D20 +41.8 (c 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.39–7.30 (m, 5H), 5.60 (td, 
J=8.8, 2.3 Hz, 1H), 5.12 (q, J=12.3 Hz, 2H), 4.56 (dd, J=4.1, 2.2 
Hz, 1H), 4.18–4.09 (m, 1H), 4.04 (dd, J=12.2, 3.6 Hz, 1H), 3.96–
3.83 (m, 2H), 3.79–3.69 (m, 1H), 2.56 (s, 3H), 2.49–2.40 (m, 
1H), 1.94–1.82 (m, 1H), 1.44 (s, 3H), 1.42 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 215.6 (C), 155.2 (C), 136.3 (C), 128.6 
(CH), 128.1 (CH), 128.0 (CH), 99.1 (C), 78.0 (CH), 67.4 (CH2), 
65.3 (CH), 62.2 (CH2), 49.1 (CH), 38.3 (CH2), 27.9 (CH3), 24.5 
(CH2), 20.0 (CH3), 19.1 (CH3); IR (ATR) v 2989, 2940, 1670, 
1422, 1220, 1058, 980, 736, 700 cm-1; HRMS (ESI) for 
C19H25NO5S2Na [M+Na]+ calculated: 434.1066; found: 434.1055. 
     AIBN (74 mg; 0.45 mmol) was added to a refluxing solution 
of xanthate (412 mg, 1.00 mmol), hypophosphorous acid (0.56 
mL of the 50% aqueous solution, 5.12 mmol) and triethylamine 
(0.8 mL, 5.73 mmol) in dioxane (9.1 mL) and the reaction 
mixture was stirred for 30 minutes at room temperature.18 Upon 
completion, the reaction mixture was diluted with 
dichloromethane (20 mL) and washed with water. The organic 
extract was dried over anh. MgSO4, filtered and concentrated 
under reduced pressure. Purification by column chromatography 
(SiO2; eluent: petroleum ether/EtOAc = 85/15), afforded the title 
compound 14 (236.8 mg,77%) as a colorless oil. [α]D20 +128.7 (c 
1.00, CHCl3); 1H NMR (500 MHz, DMSO-d6, 65 ºC) δ 7.40–7.28 
(m, 5H), 5.09 (q, J=12.6 Hz, 2H), 4.24–4.19 (m, 1H), 3.92 (dd, 
J=12.1, 4.3 Hz, 1H), 3.85 (ddd, J=10.0, 6.8, 2.8 Hz, 1H), 3.77 
(dd, J=12.1, 4.1 Hz 1H), 3.70 (q, J=4.4 Hz, 1H), 3.39 (ddd, 
J=13.1, 10.0, 6.8 Hz, 1H), 1.82–1.75 (m, 1H), 1.68–1.59 (m, 2H), 
1.58–1.49 (m, 1H), 1.38 (d, J=0.5 Hz, 3H), 1.32 (d, J=0.5 Hz, 
3H); 13C NMR (126 MHz, DMSO-d6, 65 ºC) δ 154.6 (C), 136.7 
(C), 128.0 (CH), 127.4 (CH), 127.1 (CH), 97.6 (C), 65.9 (CH2), 
63.7 (CH), 61.0 (CH2), 49.0 (CH), 37.9 (CH2), 27.7 (CH3), 23.3 
(CH2), 20.5 (CH3), 18.0 (CH2); IR (ATR) v 2989, 2941, 2874, 
1699, 1423, 1379, 1232, 1033, 768, 699 cm-1; HRMS (ESI) for 
C17H23NO4Na [M+Na]+ calculated: 328.1519; found: 328.1525.  
 
4.12. (2S,3S)-Benzyl 3-hydroxy-2-(hydroxymethyl)piperidine-
1-carboxylate (15) 
 
     A solution of amine 14 (220.0 mg, 0.72 mmol) in solvent 
mixture methanol/3M HCl (31.5 mL, v/v= 2/1) was stirred at 
room temperature for 1 h. After the volatiles were removed under 
reduced pressure, the residue was purified by column 
chromatography (SiO2; eluent: dichloromethane/methanol = 
95/5), to give the title compound 15 (137.6 mg, 72%) as a 
colorless viscous oil. [α]D20 +20.3 (c 1.00, CH2Cl2), [lit.19 ent 
[α]D25 +6.24 (c 0.25, H2O)]; 1H NMR (500 MHz, CDCl3 + drop of 
D2O) δ 7.39–7.28 (m, 5H), 5.12 (d, J=2.4 Hz, 2H), 4.52–4.43 (m, 
1H), 4.16–4.07 (m, 1H), 3.97–3.84 (m, 2H), 3.82–3.73 (m, 1H), 
3.44 (bs, 1H), 2.92 (bs, 1H), 1.87–1.80 (m, 1H), 1.75–1.68 (m, 
1H), 1.62 (ddd, J=23.9, 12.4, 4.0 Hz, 1H), 1.53–1.41 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 156.1 (C), 136.4 (C), 128.5 (CH), 
128.0 (CH), 127.7 (CH), 69.2 (CH), 67.4 (CH2), 59.1 (CH2), 
56.6 (CH), 39.8 (CH2), 28.3 (CH2), 23.6 (CH2); IR (ATR) v 3394, 
2936, 1675, 1432, 1258, 1074, 999, 738, 699 cm-1; HRMS (ESI) 
for C14H20NO4 [M+H]+ calculated: 266.1387; found: 266.1383. 
 
4.13. (2R,3S)-1-(Benzyloxycarbonyl)-3-hydroxypiperidine-2-
carboxylic acid (16) 
 
     A solution of compound 15 (52.0 mg, 0.20 mmol), 
(diacetoxy)iodobenzene (71.6 mg, 0.22 mmol) and TEMPO (8.0 
mg, 0.05 mmol, 25 mol%) in abs. dichloromethane (3.4 mL) was 
stirred at room temperature for 3 h, under an argon atmosphere.20 
The reaction was quenched by the addition of sat. aq. Na2S2O3 
(5mL) and stirred for 30 min. The mixture was extracted with 
dichloromethane (3 × 20 mL) and the combined organic extract 
was dried over anh. MgSO4, filtered and concentrated under 
reduced pressure. The residue was used without further 
purification. 
     To a stirred solution of  crude aldehyde (obtained from 15 
(52.0 mg, 0.20 mmol)) in acetonitrile (1.1 mL) was added the 
solution of  NaH2PO4•H2O (6.1 mg, 0.04 mmol) in water (0.3 
mL) and 30% H2O2 (40.0 µL, 0.51 mmol). The mixture was 
stirred and cooled at -10 °C, NaClO2 (31.2 mg, 0.34 mmol) in 
water (0.6 mL) was added dropwise over 30 min, the reaction 
mixture was then stirred at 15 °C. After 3 h, the reaction was 
quenched by addition of a small amount of Na2SO3 (11.3 mg) and 
acidified with 10% aq HC1 (5 mL). The organic layer was 
separated, aqueous layer was extracted with EtOAc (4 × 5 mL), 
the combined organic extract was evaporated, and the residue 
was dissolved in 10% aq. NaHCO3  (15 mL). The bicarbonate 
layer was washed with EtOAc (15 mL) and then made acidic to 
pH 2 and extracted with EtOAc (3 × 15 mL). The organic extract 
was dried over anh. MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by column 
chromatography (SiO2; eluent: dichloromethane/methanol = 8/2), 
to give 24.7 mg (45% over two steps) of the title compound 16, 
as a colorless viscous oil. [α]D20 +13.4 (c 0.42, CH2Cl2), [lit.19 ent 
[α]D25 -13.9 (c 0.42, CH2Cl2)]; 1H NMR (500 MHz, CDCl3) δ 
7.39–7.28 (m, 5H), 7.25–6.60 (bs, 1H), 5.20–5.12 (m, 2H), 5.12–
4.98 (m, 1H), 4.10–3.94 (m, 1H), 3.92–3.83 (m, 1H), 2.98–2.74 
(m, 1H), 2.06–1.96 (m, 1H), 1.77–1.66 (m, 1H), 1.58–1.43 (m, 
2H); 13C NMR (126 MHz, CDCl3) δ 172.2 (C), 156.7 (C), 135.8 
(C), 128.5 (CH), 128.2 (CH), 127.8 (CH), 68.6 (CH), 68.1 (CH2), 
57.6 (CH), 40.8 (CH2), 29.6 (CH2), 23.4 (CH2); IR (ATR) v 3336, 
2952, 2869, 1702, 1423, 1260, 1155, 975, 751, 699 cm-1; HRMS 
(ESI) for C14H17NO5Na [M+Na]+ calculated: 302.0999; found: 
302.0996. 
 
4.14. (2R,3S)-3-Hydroxypiperidine-2-carboxylic acid (3-
hydroxypipecolic acid, ent-3) 
 
     A suspension of compound 16 (13.2 mg, 0.05 mmol) and 10% 
Pd/C (2.0 mg, 0.002 mmol) in methanol (0.7 mL) was stirred for 
1 h under a hydrogen atmosphere (1 bar). The reaction mixture 
was filtered through celite, concentrated under reduced pressure 
and purified by column chromatography (SiO2; eluent: 
EtOAc/EtOH/H2O = 4/4/2), to give the title compound ent-3 (6.1 
mg, 90%) as a colorless, viscous oil. [α]D20 +48.3 (c 0.3, H2O), 
[lit.21 [α]D27 +51.0 (c 0.75, H2O)]; 1H NMR (500 MHz, D2O) δ 
4.56–4.51 (m, 1H), 3.70 (d, J=1.8 Hz, 1H), 3.47–3.41 (m, 1H), 
3.08–2.99 (m, 1H), 2.08–1.95 (m, 2H), 1.86–1.72 (m, 2H); 13C 
NMR (126 MHz, D2O): δ 172.3 (C), 64.1 (CH), 62.2 (CH), 43.6 
(CH2), 28.7 (CH2), 15.8 (CH2); IR (ATR) v 3060, 2928, 2856, 
1630, 1405, 1254, 1113, 998, 735 cm-1; HRMS (ESI) for 
C6H12NO3 [M+H]+ calculated: 146.0812; found: 146.0809. 
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4.15. (2S,3S)-2-(Hydroxymethyl)piperidin-3-ol (17) 
 
     A suspension of 15 (12.9 mg, 0.05 mmol) and 10% Pd/C (3.2 
mg, 0.003 mmol) in methanol (0.7 mL) was stirred for 2 h under 
a hydrogen atmosphere (1 bar). The reaction mixture was filtered 
through celite, concentrated under reduced pressure and purified 
by ion exchange column chromatography (acidic resin DOWEX 
50WX8-100), to give the title compound 17 (6.1 mg, 95%), as a 
pale yellow, viscous oil. [α]D20 +13.3 (c 0.60, H2O), ), [lit.19 ent 
[α]D25 -13.2 (c 2.51, H2O)], [α]D20 +10.8 (c 0.38, MeOH), ), [lit.22 
[α]D28 +10.8 (c 0.50, MeOH)]; 1H NMR (500 MHz, D2O) δ 4.03–
3.99 (m, 1H), 3.67 (ddd, J=19.0, 11.5, 6.7 Hz, 2H), 3.15–3.08 (m, 
1H), 2.90 (ddd, J=11.1, 7.2, 3.6 Hz, 1H), 2.72 (td, J=12.4, 3.2 
Hz, 1H), 1.93–1.86 (m, 1H), 1.82–1.68 (m, 2H), 1.60–1.53 (m, 
1H); 13C NMR (126 MHz, D2O) δ 64.4 (CH), 61.4 (CH2), 59.5 
(CH), 44.3 (CH2), 29.7 (CH2), 18.9 (CH2); IR (ATR) v 3308, 
2937, 2863, 1596, 1440, 1099, 1037, 993, 734 cm-1. 
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